The MDL focuses on non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition linked to sudden vision impairment
Thus, preventing muscle loss during weight reduction can help maintain higher levels of energy expenditure and avoid weight regain
The primary endpoint was weight loss at 12 months, with secondary endpoints including remission of obesity-related conditions such as type 2 diabetes, hypertension, and hyperlipidemia
Gruesser (all EASD, Dusseldorf, Germany), the Committee for Clinical Affairs of the EASD and the Professional Practice Committee of the ADA
Additionally, in another Phase II study targeting patients with T2DM, orforglipron also showed significant effects in reducing A1C and weight, achieving the studys primary and secondary endpoints
Some side effects are known and documented